Open-label exploratory study of fosigotifator in vanishing white matter disease

Phase 2, open-label trial of fosigotifator in leukoencephalopathy with vanishing white matter (VWM) (5 cohorts), sponsored by Calico Life Sciences. Primary endpoints: Adverse events and serious adverse events during the Safety Evaluation Period, Vital signs, ECGs, clinical laboratory tests, and suicidality assessments during the Safety Evaluation Period and 3 more. Started Mar 2024; status: recruiting.